The management of choroid plexus carcinoma (CPC) is challenging and multifaceted. Here, we discuss a 3-year-old girl with CPC and Li-Fraumeni syndrome who achieved full remission after surgery and chemotherapy, with radiation therapy spared. At recurrence, we used a novel, standard-dose cytotoxic chemotherapy regimen, focal proton radiation therapy, and targeted agents based on morphoproteomic analysis to achieve long-term survival. We highlight the rationale for our therapy at recurrence, as well as the risk-benefit analyses necessary in decision making for these patients. Our strategy may be effective in managing other patients with recurrent CPC and Li-Fraumeni syndrome.
*Department of Pediatrics, University of Colorado School of Medicine
†Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Aurora, CO
‡Pediatric Neuro-Oncology, Children’s Hospital Los Angeles, Los Angeles, CA
§Department of Pediatric Oncology, Dana-Farber Cancer Institute
∥Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
¶Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI
#Department of Pathology, UTHealth McGovern Medical School, Houston, TX
**AbbVie, Chicago, IL
The authors declare no conflict of interest.
Reprints: Adam L. Green, MD, University of Colorado Anschutz Medical Campus, 12800 E. 19th Avenue, Mail Stop 8302, Aurora, CO 80045 (e-mail: email@example.com).
Received December 16, 2016
Accepted July 24, 2017